The latest announcement is out from Proteomics International Laboratories Ltd. ( (AU:PIQ) ).
Proteomics International Laboratories Ltd announced that its PromarkerD test significantly outperforms standard tests in predicting kidney decline in type 2 diabetes, as published in the journal Diagnostics. This advancement could revolutionize diabetic kidney disease management, offering earlier intervention and reducing healthcare costs, with the potential to impact over 537 million people worldwide. The company has opened a Reference Laboratory in California and plans to launch PromarkerD in Australia, initially through a direct-to-consumer approach.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on developing advanced diagnostic tests. The company is expanding its commercial operations in the US and Australia, aiming to improve health outcomes globally.
YTD Price Performance: -41.88%
Average Trading Volume: 164,874
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$60.92M
Learn more about PIQ stock on TipRanks’ Stock Analysis page.